Saghiri Mohammad A, Saini Ravinder S, Heboyan Artak
Department of Restorative Dentistry, Director of Biomaterial and Prosthodontic Laboratory, Rutgers School of Dental Medicine, Newark, NJ, USA.
Department A. Dental Health Sciences COAMS, King Khalid University, Abha, Saudi Arabia.
Cancer Control. 2025 Jan-Dec;32:10732748241310936. doi: 10.1177/10732748241310936.
Oral cancer remains 1 of the biggest health care challenges; it has a poor response to treatment, and treatment often results in severe side effects. Nano-targeted drug carrier-assisted drug delivery systems can improve the benefits of targeted drug delivery and treatment efficacy. A systematic review and meta-analysis was conducted to investigate the effect of targeted nano carrier drug delivery systems on the management of oral cancer.
A comprehensive literature search was performed using PubMed, ScienceDirect, the Cochrane Library, Google Scholar, and Scopus using PRISMA guidelines, to identify relevant in vitro and in vivo (human) studies. Studies evaluating the impact of nanocarrier-based delivery systems on oral cancer cells or human models were selected. Pooled effect sizes were calculated using random-effects models via RevMan 5.4, and heterogeneity among studies was assessed.
After full-text assessment, 15 research articles were included [14 in vitro studies and 1 randomized controlled trial (RCT)]. In the meta-analysis, the pooled data (IC) for the impact of the nanocarrier delivery system vs control on oral cancer was -7.67 (95% CI: -41.77, 26.43), with a high heterogeneity ( = 92%, < 0.00001). Moreover, in vitro studies had a medium risk of bias, while the RCT had some concerns in the randomization domain.
Nanocarrier-based drug delivery has been found to be a superior approach compared to drug delivery in free form, increasing the efficacy and safety of oral cancer treatment.
口腔癌仍然是最大的医疗保健挑战之一；其对治疗反应不佳，且治疗常常导致严重的副作用。纳米靶向药物载体辅助给药系统可以提高靶向给药的效益和治疗效果。进行了一项系统评价和荟萃分析，以研究靶向纳米载体给药系统对口腔癌治疗的影响。
按照PRISMA指南，使用PubMed、ScienceDirect、Cochrane图书馆、谷歌学术和Scopus进行全面的文献检索，以确定相关的体外和体内（人体）研究。选择评估基于纳米载体的给药系统对口腔癌细胞或人体模型影响的研究。通过RevMan 5.4使用随机效应模型计算合并效应量，并评估研究之间的异质性。
经过全文评估，纳入了15篇研究文章[14篇体外研究和1项随机对照试验（RCT）]。在荟萃分析中，纳米载体给药系统与对照组对口腔癌影响的合并数据（IC）为-7.67（95%CI：-41.77，26.43），异质性较高（I² = 92%，P < 0.00001）。此外，体外研究存在中度偏倚风险，而RCT在随机化领域存在一些问题。
与游离形式的药物给药相比，基于纳米载体的药物给药已被发现是一种更优的方法，可提高口腔癌治疗的疗效和安全性。
